Monday, July 18, 2011

SARcode Bioscience Gets $44M

Brisbane-based SARcode Bioscience, a firm developing treatments for inflammatory disease, said this morning it has raised $44M in a Series B financing round. The round was led by Sofinnova Ventures, and also included Rho Ventures, Alta Partners, and Clarus Venture Partners. The firm said the funding goes towards clinical development of its product for "dry eye" syndrome, an inflammatory disease affecting approximately 20 million people in the U.S. More information »